Bcl‐2, Bcl‐xL, and Mcl‐1 are significantly overexpressed in myeloma cells, and are considered to be among the major contributing factors to the survival, growth, and chemo‐resistance of myeloma.32, 34 Therefore, targeting these proteins represents an attractive therapeutic strategy. The gene discussed is BCL2; the disease is plasma cell myeloma.